Updated:
Kansas Bioscience Authority
Kansas Bioscience Authority invests state-allocated capital in bioscience companies and research, with over $400M deployed and $1.5B in co-investment...
Kansas Bioscience Authority
The Kansas Bioscience Authority (KBA) was created in 2004 as a state-chartered entity with a unique mandate: invest public money to stimulate bioscience innovation and job creation in Kansas. It was capitalized with $580 million in state bonds over 15 years, making it one of the largest state-level bioscience investment funds in the U.S. KBA operates as an independent public authority, not a traditional family office or venture firm. KBA deploys capital across the bioscience spectrum — from early-stage research through commercialization. Its investment toolkit includes seed and venture capital, direct investments in startups, grants to university researchers, and matching funds for federal grants. Targeted sectors include human health therapeutics, medical devices, animal health, agricultural biotechnology, and industrial biotechnology. Notable portfolio companies have included Aratana Therapeutics (animal health, IPO 2013) and Deciphera Pharmaceuticals (oncology, IPO 2017). KBA also co-invests with private venture firms and corporate partners, primarily in the Kansas City region but also statewide. By 2022, KBA had invested over $400 million in Kansas bioscience companies and research institutions, leveraging an additional $1.5 billion in private and federal co-investment (per the Kansas City Business Journal, 2022). The authority maintains a lean team with offices in Olathe and satellite locations in Basel, Chicago, Washington D.C., Durham, and Burlington. Its activities are overseen by a board of directors appointed by the governor and legislative leaders. In 2021, the Kansas legislature restructured KBA, shifting its governance to align with economic development priorities (per the Kansas Legislature, 2021). KBA's structural differentiator is its public-private hybrid model: it uses state-appropriated funds for catalytic investments that private capital alone would not support, but it operates with the discipline of a venture investor. Unlike a typical state grant program, KBA takes equity positions and seeks financial returns, reinvesting profits into new Kansas bioscience ventures. This self-sustaining model has been emulated by other states but remains rare in practice.
General information
Firm type
Foundation
Year founded
2004
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Olathe
Corporate office
Olathe, KS, United States
Additional offices
Basel, Switzerland · Chicago, IL · Washington, D.C. · Durham, NC · Burlington, MA
Sector focus
Frequently asked questions
Who makes investment decisions at the Kansas Bioscience Authority?
KBA is governed by a board of directors appointed by the Kansas governor and legislative leaders. The board sets investment strategy and approves major commitments. Day-to-day investment management is handled by a professional staff, though specific named executives are not publicly listed. (per KBA state statute, 2004)
How does KBA source proprietary deal flow?
KBA sources deals through its network of university research partners — including the University of Kansas Medical Center and Kansas State University's College of Veterinary Medicine — as well as through direct outreach to Kansas-based bioscience startups. It also receives referrals from venture capital firms active in the region. (per Kansas City Business Journal, 2022)
Is KBA structured as a venture capital firm or a government agency?
KBA is a hybrid — a state-chartered public authority that operates with venture-like investment discipline. It can take equity positions, make direct investments, and seek financial returns, but it was created by state legislation and is beholden to public oversight. Its mandate is economic development, not maximizing return. (per KBA enabling statute, 2004)
What investment stages does KBA typically target?
KBA invests across the full spectrum of bioscience development — from early-stage university research grants and seed rounds to growth-stage venture capital and commercialization support. It often fills gaps where private capital is scarce, such as translational research or first-in-human clinical trials. (per Kansas City Business Journal, 2022)
Which sectors does KBA explicitly avoid?
KBA's mandate limits investments to bioscience and related technologies. It does not invest in software, financial services, real estate, or other non-bioscience sectors. Within bioscience, it focuses on human and animal health, agriculture, and industrial biotechnology. (per KBA enabling statute, 2004)
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: